FDA Approves Maraviroc, First Drug in New Class of Anti-HIV Medications
On August 6, 2007, the United States Food and Drug Administration (FDA) approved maraviroc (Selzentry), the first drug to be approved in the CCR5 coreceptor antagonist class of anti-HIV medications. Maraviroc has been approved for use in conjunction with other antiretrovirals in treatment-experienced adults who have exclusively CCR5-tropic HIV virus, evidence of viral replication, and resistance to multiple antiretroviral medications.
More information about maraviroc and related topics is also available:
- FDA: Official maraviroc approval press release
- AIDSinfo: Drug database featuring an updated maraviroc drug record and information on other approved and investigational entry and fusion inhibitors
- AIDSinfo: HIV Life Cycle fact sheet
- ClinicalTrials.gov: Clinical trials involving maraviroc
- PubMed: Journal articles on maraviroc
AIDSinfo Launches Audio Drug Name Pronunciations
In response to requests for pronunciations of anti-HIV drug names, the AIDSinfo drug database can now tell visitors how to say the name of a drug! Simply click on the speaker icon next to the name of any drug in the database to hear it pronounced.
AIDSinfo: Drug Database